## **ACTIN Report**

PATIENT ACTN-01-02-9999

REPORT DATE
26-Jan-2022

Sample ID: ACTN01029999T | Gender: Male | Birth year: 1950 | WHO: 1

Tumor: Skin - Melanoma | Stage: IV

### Summary

Patient clinical history (16-Jan-2022)

Relevant systemic treatment history Vemurafenib (1/2021), Ipilimumab (2022)

Other oncological history Resection (2020)

Previous primary tumor: Bone/Soft tissue Schwannoma (1/2019, considered active)

Relevant non-oncological history Pancreatitis, Myocardial infarction

Patient current details (16-Jan-2022)

Unresolved toxicities grade => 2 Fatigue (2), Dizziness
Significant aberration on latest ECG Atrial arrhythmia

Cancer-related complications Ascites

Tumor details (16-Jan-2022)

Biopsy location Liver

Lesion locations CNS (active, not symptomatic), Liver, Pulmonal, Abdominal

Measurable disease (RECIST)

Laboratory results (16-Jan-2022)

Liver function Total bilirubin

ASAT (< 33 U/I) 36 U/I (no trend information available)

ALAT ALP Albumin

Kidney function Creatinine

CKD-EPI eGFR (> 100 mL/min) > 100 mL/min (27-Dec-2021)

Other Hemoglobin (6.5 - 9.5 mmol/L) 5.5 mmol/L (no trend information available)

Thrombocytes (155 - 350 10\*9/L) 150 10\*9/L (out of range for 2 cons. measurements, trend down)

LDH (< 245 U/L) **240 U/L (06-Jan-2022)** 

Molecular results (WGS, 21-Jan-2022)

Molecular results have reliable quality Yes

Events with trial eligibility in ACTIN database BRAF V600E, High TML

Events with responsive evidence in CKB BRAF V600E, High TML

PATIENT ACTN-01-02-9999

REPORT DATE 26-Jan-2022

# **Treatment Options**

# **Trial Eligibility Summary**

# Trials evaluated

Trials considered potentially eligible 1 (Test Trial)

# Cohorts evaluated

Cohorts considered potentially eligible 2 (Test Trial - Cohort B, Test Trial - Cohort C)

Open cohorts considered potentially eligible 2 (Test Trial - Cohort B, Test Trial - Cohort C)

### **Trial Matching Summary**

Trial / Cohort	# Criteria	# Passed	# Warnings	# Failed	# Undetermined	# Not evaluated	# Non-implemented
Test Trial	3	2	0	0	0	1	0
Test Trial - Cohort A	1	0	0	1	0	0	0
Test Trial - Cohort B	0	0	0	0	0	0	0
Test Trial - Cohort C	0	0	0	0	0	0	0

PATIENT ACTN-01-02-9999

REPORT DATE
26-Jan-2022

# **Trial Matching Details**

#### **Test Trial**

Evaluation PASS

Acronym TEST-TRIAL

Title This is an ACTIN test trial

Rule Reference Evaluation PASS I-01 Is adult NOT\_EVALUATED E-01 This rule has 2 conditions: 1. Patient has no symptomatic CNS metastases. 2. Patient has exhausted SOC. E-01 This rule has 2 conditions: PASS 1. Patient has no symptomatic CNS metastases. 2. Patient has exhausted SOC.

#### **Test Trial - Cohort A**

Cohort ID A
Evaluation FAIL
Open for inclusion? Yes

 Rule
 Reference
 Evaluation

 I-02
 Has no active CNS metastases
 FAIL

### **Test Trial - Cohort B**

Cohort ID B
Evaluation PASS
Open for inclusion? Yes

#### **Test Trial - Cohort C**

Cohort ID C
Evaluation PASS
Open for inclusion? Yes